REG - GenIP PLC Tekcapital plc - New Orders

TekcapitalAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU1668Fa&default-theme=true

RNS Number : 1668F  GenIP PLC  21 May 2026

 

 

21 May 2026

 

GenIP Plc

("GenIP" or the "Company")

 

New Orders

GenIP Plc (AIM: GNIP), a technology consultancy providing AI-driven services
to help research organisations and corporations commercialise their
innovations, is pleased to announce the following new orders.

#1 Ranked Research University in Hong Kong

The Company has entered into a 12-month framework agreement with a leading
Hong Kong research university, with an option to renew for a further 12
months. The agreement enables portfolio-level evaluations of up to 10
technologies per order, with orders placed by the university as required. The
engagement is valued at approximately $20,000 per year, with potential for
additional work beyond the initial scope.

Major UK Higher Education Institution

The Company has secured a first-time engagement with a well-established modern
university in London, recognised for its strengths in applied research,
engineering, and technology. The initial order covers 10 reports, with the
likelihood of additional repeat orders to evaluate the institution's broad
innovation portfolio.

South African Client: Invention Validator

A South African client has deployed the Company's recently launched Invention
Validator product, representing one of the first engagements for this
offering. The engagement is valued at approximately $14,500 for a single
technology evaluation. The product is currently operating with a 60% margin
floor, supporting strong unit economics as adoption scales.

Canadian and US Research Universities

The Company has secured its first Canadian client, one of Canada's leading
research universities, with over 65,000 students and a strong international
reputation in AI, engineering, health sciences, and technology research. The
Company has also secured an engagement with one of North America's leading
public research universities, internationally recognised for its programmes in
engineering, AI, computer science, and technology innovation. Comparable
institutions place orders monthly, and we are confident we'll maintain a
similar relationship with our new clients.

The Company will announce their FY2025 results within the next two weeks and
will include an outlook at that time.

Melissa Cruz, CEO of GenIP, commented:

"Securing a framework agreement with the #1 ranked university for patent
influence in China is a major validation of our new AI-driven products.

 

More broadly, we are delighted with the response to our expanding range of
products and believe GenIP is perfectly positioned for another year of
top-line growth in 2026 as the number of long-term repeat customers grows."

 

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                                 Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                              Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 AlbR Capital Limited (Joint Broker)                                       Tel: +44 (0)20 7399 9427

 Colin Rowbury                                                             cr@albrcapital.com (mailto:cr@albrcapital.com)

 Jon Belliss                                                               Jb@albrcapital.com (mailto:Jb@albrcapital.com)

                                                                           Tel: + 44 (0) 203 003 8632

 CMC Markets (Joint Broker)

 Douglas Crippen

                                                                           genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 Redchurch Communications (Financial PR)

 John Casey

 

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation business      at the intersection of
generative AI and innovation strategy. We empower corporates, venture funds,
and research institutions to evaluate, commercialise, and scale breakthrough
technologies. By combining proprietary GenAI algorithms with expert human
analysis, GenIP delivers decision-grade insights and talent solutions that
accelerate innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                     Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of    Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                           investment, and IP strategy
 IP Commercialization Services         End-to-end engagement to help research organisations commercialise innovations  Provides cost-effective, broad support to achieve our clients' strategic

                                                                               objectives

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●    Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEAPSEADDKEFA



            Copyright 2019 Regulatory News Service, all rights reserved